CAMBRIDGE, Mass., April 30, 2025 — GentiBio, a leading biotechnology company focused on developing engineered regulatory T cells (Tregs) to treat immune-mediated diseases, today announced its participation at the 2025 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting and the American Association of Immunologists (AAI) Annual Meeting. The company will present new data through a set of nine accepted posters and talks supporting the broad therapeutic potential of its pipeline of engineered Tregs across multiple autoimmune, inflammatory, ischemic disease indications and novel hypo-immune technology wholly developed and owned by GentiBio.
At ASGCT 2025, GentiBio will present six abstracts, including a late-breaking poster and a podium presentation, showcasing its cutting-edge work in tissue engineered Tregs, proprietary allogeneic hypo-immune technology, and disease-specific Treg designs:
- Talk [Session: CAR-T Innovations in Autoimmune and Infectious Disease 5/15 3:45-5:30pm CDT]: CAR19 Engineered Regulatory T Cells, a Novel Approach for Immune Reset in B and T Cell Mediated Autoimmune Disorders
- Poster [1249, 5/14 5:30-7:00pm CDT]: A Novel NK Inhibitor Provides “Best-in-Class” Protection of HLA Knockout Allogeneic Human Engineered Regulatory T Cells to Effectively Evade Immune Rejection
- Poster [1047, 5/14 5:30-7:00pm CDT]: Development of Tissue Engineered Tregs for the Treatment of Ischemic Stroke and Neurodegenerative Diseases
- Poster [1769, 5/15 5:30-7:00pm CDT]: A Stable Engineered Regulatory T Cell Therapy Platform with Modular Targeting for Autoimmune and Inflammatory Diseases
- Poster [1528, 5/15 5:30-7:00pm CDT]: Allogeneic Engineered T Regulatory Cells Improve Disease Outcome in Preclinical Models of Acute Lung Injury
- Late-Breaking Poster [2031, 5/14 5:30-7:00pm CDT]: GNTI-932: A Gut-Specific CAR-Engineered T Regulatory Cell Therapy to Treat Inflammatory Bowel Disease
At AAI 2025, GentiBio will highlight preclinical data on tissue-targeted and CAR-engineered Treg platforms demonstrating efficacy in models of inflammation and immune dysregulation:
- Talk [Symposium TI2: Translational and interventional Immunology, 5/7 7:15am HST]: Engineered Tissue Tregs Ameliorate Inflammatory and Ischemic Diseases
- Poster [1069, 5/04 10:30-11:45am HST]: Development of Allogeneic Tissue Engineered T Regs for the Treatment of Ischemic Stroke and Acute Lung Injury
- Poster [1106, 5/04 2:15 – 3:30pm HST]: CAR19 EngTregs Offer Broad Capacity to Modulate Immune Tolerance and Improve Safety in B and T Cell Mediated Autoimmune Disorders
“These presentations reflect GentiBio’s continued momentum in expanding the therapeutic potential of engineered Tregs to treat inflammatory disorders and restore immune tolerance across a range of indications,” said Tom Wickham, CSO “We look forward to connecting with collaborators and peers at both meetings to share our progress and explore new opportunities in Treg cell therapy.”
GentiBio’s lead program, GNTI-122, heads to the clinic with the start of the POLARIS study in the second half of 2025, to treat recently diagnosed Type 1 Diabetes patients. The Genti team plans to present updates on the GNTI-122 program and POLARIS study at ENDO and ADA 2025 conferences this summer.
About GentiBio
GentiBio, Inc. is a biotherapeutics company co-founded by pioneers in Treg biology and immunology from Seattle Children’s Research Institute and Benaroya Research Institute to develop engineered regulatory T cells programmed to treat autoimmune and inflammatory diseases. GentiBio’s Series A financing was led by Matrix Capital Management with participation by Avidity Partners, JDRF T1D Fund, seed investors OrbiMed, RA Capital Management, Novartis Venture Fund, and Seattle Children’s Research Institute. GentiBio’s autologous and allogeneic engineered Tregs platforms integrate key technologies designed to successfully (re)establish immune tolerance and overcome major limitations in existing Treg therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that has the potential to address the fundamental cause of many diseases that result from overactivity and/or malfunctioning of the immune system. To learn more, visit www.gentibio.com
Media Contact:
Hatem Heikal
Vice President, Finance
Hatem.Heikal@GentiBio.com